Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H6ClN3O6.2C4H11NO3 |
Molecular Weight | 553.905 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(CO)(CO)CO.NC(CO)(CO)CO.OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N
InChI
InChIKey=JJOFNSLZHKIJEV-UHFFFAOYSA-N
InChI=1S/C11H6ClN3O6.2C4H11NO3/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21;2*5-4(1-6,2-7)3-8/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21);2*6-8H,1-3,5H2
Molecular Formula | C11H6ClN3O6 |
Molecular Weight | 311.635 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H11NO3 |
Molecular Weight | 121.135 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.drugbank.ca/drugs/DB06794
http://www.rxlist.com/alomide-drug.htm
Curator's Comment: Description was created based on several sources, including
http://www.drugbank.ca/drugs/DB06794
http://www.rxlist.com/alomide-drug.htm
Lodoxamide is a mast-cell stabilizer for topical administration into the eye. This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. Lodoxamide inhibits the in vivo Type I immediate hypersensitivity reaction. In vitro, Lodoxamide stabilizes mast cells and prevents antigen-stimulated release of histamine. In addition, Lodoxamide prevents the release of other mast cell inflammatory mediators and inhibits eosinophil chemotaxis. Although Lodoxamide's precise mechanism of action is unknown, the drug has been reported to prevent calcium influx into mast cells upon antigen stimulation. Among side effects to Lodoxamide, the most frequently reported ocular adverse experiences were transient burning, stinging, or discomfort upon instillation. Nonocular events reported were headache and heat sensation, dizziness, somnolence, nausea, stomach discomfort, sneezing, dry nose, and rash.
Originator
Sources: http://www.google.com.na/patents/DE2362409A1?cl=en
Curator's Comment: Additional resources: http://www.google.ch/patents/US3993679 http://www.drugfuture.com/chemdata/lodoxamide.html http://www.ncbi.nlm.nih.gov/pubmed/102796 https://books.google.ru/books?id=0vXTBwAAQBAJ&pg=PA737&lpg=PA737&dq=N,N%E2%80%99-++%282-chloro-5-cyano-m-phenylene%29dioxamic++acid&source=bl&ots=6ITmv3Yzuw&sig=F7WQDCB_NG3dR476ZXvS5xZqkg4&hl=ru&sa=X&ved=0ahUKEwipi6e05NnLAhVnYpoKHQOHDSkQ6AEIKzAC#v=onepage&q=N%2CN%E2%80%99-%20%20%282-chloro-5-cyano-m-phenylene%29dioxamic%20%20acid&f=false
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0097279 |
|||
Target ID: GO:0048245 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9652307 |
|||
Target ID: GO:0016068 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ALOMIDE Approved UseALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. Launch Date1993 |
|||
Curative | ALOMIDE Approved UseALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. Launch Date1993 |
|||
Curative | ALOMIDE Approved UseALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. Launch Date1993 |
PubMed
Title | Date | PubMed |
---|---|---|
Lodoxamide in vernal keratoconjunctivitis. | 1996 May |
|
[Evaluation of the efficacy and safety of lodoxamide in patients with allergic eye diseases]. | 2002 |
|
[In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter]. | 2003 Apr |
|
Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis. | 2003 Apr |
|
Vernal keratoconjunctivitis in Thailand. | 2003 Mar |
|
Tear and serum eosinophil cationic protein levels in seasonal allergic conjunctivitis. | 2003 Oct |
|
Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1. | 2009 Jun 15 |
|
Updates in the treatment of ocular allergies. | 2010 Nov 24 |
|
Safety and efficacy of lodoxamide in vernal keratoconjunctivitis. | 2011 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: The dose for adults and children greater than two years of age is one to two drops in each affected eye four times daily for up to 3 months.
1-2 drops in each affected eye four times daily
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9652307
Lodoxamide exerts dose-dependent inhibitory effects on human eosinophil chemotactic response to fMLP, reaching more than 60% inhibition at 100 ng/ml and 80% inhibition for 10 ug/ml lodoxamide.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:18:09 GMT 2023
by
admin
on
Fri Dec 15 15:18:09 GMT 2023
|
Record UNII |
50LV9A548L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29714
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
||
|
FDA ORPHAN DRUG |
59791
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11192129
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
DB06794
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
SUB02964MIG
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
63610-09-3
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
50LV9A548L
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
m6883
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | Merck Index | ||
|
28859
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID20979825
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
100000092604
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201266
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
C022028
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
50LV9A548L
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY | |||
|
C29160
Created by
admin on Fri Dec 15 15:18:09 GMT 2023 , Edited by admin on Fri Dec 15 15:18:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |